Filtered By:
Specialty: Drugs & Pharmacology
Procedure: Coronary Artery Bypass Graft

This page shows you your search results in order of date.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Emergency coronary artery bypass surgery in octogenarians with acute coronary syndrome: off and on pump
CONCLUSIONS: We showed that emergency OPCAB as a revascularization option in elderly patients with acute coronary syndrome is more advantageous in terms of preventing major postoperative complications.PMID:37606114 | DOI:10.26355/eurrev_202308_33277
Source: European Review for Medical and Pharmacological Sciences - August 22, 2023 Category: Drugs & Pharmacology Authors: E E Tekin B Aydinli M A Yesiltas D Oksen Source Type: research

Effect of Nicorandil, Diltiazem, or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts —A Pilot Randomized Controlled Trial (ASRAB-Pilot): Rationale and Study Protocol
ConclusionThis pilot trial will compare the preliminary effects of nicorandil, diltiazem, and isosorbide mononitrate on angiographic and clinical outcomes in patients who have undergone RA-CABG. Recruitment began in June 2020, and the estimated primary completion date is early 2023. Results of this study will provide much needed information for design of large confirmatory trials on the effectiveness of oral antispastic medications after RA-CABG.
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research

Safety and Efficacy of Tirofiban Bridging Therapy During a Hybrid Carotid Artery Stenting and Off-Pump Coronary Artery Bypass Grafting Surgery: A Single-Center Study
This study evaluated the safety and efficacy of tirofiban as a bridging therapy after a hybrid CAS + CABG surgery.METHODS: Between June 2018 and February 2022, a total of 45 patients undergoing a hybrid CAS + off-pump CABG surgery were divided into either the control group (standard dual antiplatelet therapy postsurgery, n = 27) or the tirofiban group (tirofiban bridging + dual antiplatelet therapy, n = 18). The 30-day outcome was compared between the 2 groups, and the primary end points included stroke, postoperative myocardial infarction, and death.FINDINGS: Two patients (7.41%) from the control group experienced a strok...
Source: Clinical Therapeutics - February 21, 2023 Category: Drugs & Pharmacology Authors: Changcheng Liu Shipan Wang Yuan Xue Jiantao Wang Haiyang Li Source Type: research